Product Information
| Molecular Weight | 223.3 g/mol |
| Purity | >98% |
| Molecular Formula | C7H5N5S2 |
| CAS | 2645-32-1 |
| Solubility | Soluble in DMSO at 5 mg/mL. |
PR-619 is a small-molecule inhibitor that displays broad specificity toward several deubiquitylating enzymes, including members of the ubiquitin specific protease (USP) and the ubiquitin C-terminal hydrolase (UCH) subfamilies (1). The ubiquitin proteasome system involves protein ubiquitination by ubiquitinating enzymes followed by proteasomal degradation; the process is reversed by cysteine proteases known as deubiquitinating enzymes that cleave ubiquitin from ubiquitin-conjugated proteins (2). PR-619 treatment of cells resulted in the accumulation of polyubiquitinated proteins and was not related to any deficiency in proteasome activity (1). Likewise, PR-619 treatment of an oligodendroglial cell line led to the buildup of protein aggregates near the microtubule network and increased expression of heat shock proteins associated with the cellular stress response (3). Protein deubiquitination is related to the development of cisplatin-resistant metastatic bladder urothelial carcinoma in patients; PR-619 treatment was shown to relieve chemoresistance in urothelial carcinoma cells and in a mouse xenograft model (4).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
| Cat. # | Size | Qty. | Price |
|---|---|---|---|
| 26065S | 5 mg |
|
